You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Demand Driven Healthcare Scheduling using Flexible Shifts and Monte-Carlo Simulat

    SBC: Acme Express, Inc.            Topic: NINR

    DESCRIPTION (provided by applicant): The shortage of nurses and medical technologists is accelerating. Shortages can be reduced by scheduling staff to precisely meet the hour-by-hour demand for medical service. Think of bank teller scheduling, where more staff are scheduled at peak demand. Current attempts to schedule to demand are relatively primitive: a small number of quantized fixed shifts, fo ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Refinement of lead compounds to modulate water permeability through AQP4

    SBC: AEROMICS, Inc.            Topic: NINDS

    DESCRIPTION (provided by applicant): Cerebral edema (and its counterpart in the spinal cord) is a major contributor to the damage caused by stroke, traumatic brain injury, traumatic spinal-cord injury, and bacterial meningitis. Stroke alone is the third leading cause of death in the USA and the leading cause of disability. Unfortunately, few treatment options are available for cerebral and spinal- ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Combination Treatment of tPA and Apyrase for Stroke

    SBC: APT THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for most patients. Using a protein informatics approach, we have successfully engineered a human apyrase which exhibits significantly higher enzymatic activity and platelet inhibition than the wild-type ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Combination Therapy of Aspirin and Apyrase for Stroke

    SBC: APT THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for most patients. This enzyme strongly inhibits platelet activation and aggregation with modest bleeding risk. We will validate hypothesis that in thromboembolic model of stroke in rats, combination tre ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Therapeutic Potential of Ex vivo expanded Human Cord Blood derived CD133+ cells i

    SBC: Arteriocyte, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Critical Limb Ischemia (CLI) is a common problem that often results in major limb amputation. Circulating endothelial progenitor cells likely play a role in the pathogenesis of CLI; the number and function of these cells that are mobilized from the bone marrow are reduced in the elderly and diabetics, groups at high risk for CLI. Allogenic Umbilical Cord Blood ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  6. A Novel Expansion of Primary Leukemia Stem Cells

    SBC: Arteriocyte, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Arteriocyte's long-term objective is to develop a platform for ex vivo expansion of leukemic stem cell (LSC) based on cytokine-enriched medium and the company's proprietary nanofiber culture scaffold (NANEX). Cancer stem cell research is of significant importance because, this approach has the potential to create an effective therapy that overcomes challenges o ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Halogenated Insulin: a fast-acting, ultra stable analog.

    SBC: THERMALIN DIABETES, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): A Phase 1 SBIR program of pre-clinical development is proposed focusing on a novel rapid-acting insulin analog for the treatment of diabetes mellitus. Designated Insulin-Cl, our product is a derivative of insulin lispro (the active component of HumalogTM) containing a single chloro-substitution within the aromatic ring of a conserved phenylalanine in the B-chai ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. A Novel 'Zinc-Stapled' Long-Acting Insulin Analog

    SBC: THERMALIN DIABETES, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): A Phase 1 SBIR program of pre-clinical development is proposed focusing on a novel long-acting insulin analog for the basal treatment of diabetes mellitus. Designated Insulin-ZN, our product is a derivative of human insulin containing novel zinc-binding sites at the periphery of the insulin hexamer. The non-classical zinc-binding sites are mediated by paired (i ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Optimization of the angiogenic potential of multipotent adult progenitor cells

    SBC: ATHERSYS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Peripheral Vascular Disease (PVD) results from chronic loss of the oxygen supply to the lower limbs due to arterial blockage. Loss of oxygen to these tissues can result in pain, ulcers, infection and limb amputation in patients. PVD affects up to 12% of the population globally with increased risk in patients with diabetes, hypertension, advanced age and obesity ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. TGF-beta Antagonists for Accelerating Wound Healing

    SBC: AUXAGEN, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Every year in the United States, gt1.25 million people suffer from burns, 6.5 million have chronic skin ulcers caused by pressure, venous stasis or diabetes mellitus and 0.25 million have keloids sufficiently severe to require surgery. Burn treatment costs 1.8 billion per year in the US. The treatment of persons with chronic skin ulcers costs 13 billion per y ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government